{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-003851","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.017776+00:00","generated_at":"2026-05-16T19:52:00.286230+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Entera Bio reports Q3 net loss $3.2M; FDA agrees BMD endpoint for EB613 Phase 3","bullets":["Net loss $3.2M ($0.07/share) vs $3.0M ($0.08/share) in Q3 2024; cash $16.6M through mid-Q3 2026.","FDA agreed BMD as primary endpoint for single Phase 3 trial of EB613 (oral PTH) for osteoporosis; supports NDA.","EB613 Phase 2 data showed significant BMD gains in younger postmenopausal women, presented at NAMS and ASBMR.","Next-gen EB613 Phase 1 trial on track for late 2025; GLP-2 and OXM programs with OPKO advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-003851","json":"https://secwatch.observer/filing/0001178913-25-003851.json","markdown":"https://secwatch.observer/filing/0001178913-25-003851.md","text":"https://secwatch.observer/filing/0001178913-25-003851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325003851/0001178913-25-003851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891325003851/zk2534017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:52:00.286230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}